Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-03
2007-07-03
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263380, C514S263370, C544S276000, C544S277000
Reexamination Certificate
active
10837290
ABSTRACT:
Disclosed are novel A2Badenosine receptor antagonists of Formula I:A compound of the formula:wherein:R1is optionally substituted alkyl or a group —Y-Z, in which Y is a covalent bond or optionally substituted alkylene, and Z is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted alkenyl or optionally substituted alkynyl, with the proviso that when Y is a covalent bond Z cannot be alkenyl or alkynyl; andX is oxygen, sulfur, or NH—,or a pharmaceutically acceptable salt, ester, or prodrug thereof. The compounds are particularly useful for treating asthma and diabetic retinopathy.
REFERENCES:
patent: 2003/0149060 (2003-08-01), Cristalli
patent: 2004/0048868 (2004-03-01), Edwards et al.
patent: 2004/0204428 (2004-10-01), Giorgio et al.
Palle Venkata
Varkhedkar Vaibhav
Xiao Dengming
Zablocki Jeff
Berch Mark L.
CV Therapeutics Inc.
CV Therapeutics, Inc.
Hartrum J. Elin
Lewis Brian
LandOfFree
A 2B adenosine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with A 2B adenosine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A 2B adenosine receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3805087